Mayo Clinic | Strategic Alliance Partners

Latest from Mayo Clinic


Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

January 08, 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC

December 20, 2020

Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation TKI, and ongoing research efforts to further improve care.

BCMA-Targeted ADC MEDI2228 Induces Deep Responses in Heavily Pretreated Myeloma

December 09, 2020

December 9, 2020 — The BCMA-targeted antibody-drug conjugate MEDI2228 showed promising clinical efficacy in patients with relapsed/refractory multiple myeloma, with triple-refractory disease experiencing maintained responses.